FDA approves Xalkori(crizotinib) with companion diagnostic(from $ABT) for a type of late-stage lung cancer(ALK+ NSCLC). note the PDUFA was originally November 16th.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.